Drugs Standards

A section of Standards (ISSN 2305-6703).

Section Information

The MDPI journal Standards has established a new Section called Drug Standards in order to meet the growing challenges of standardization in the global pharmaceutical market. Within our Section, we welcome contributions referring to these challenges in all stages of the drug life cycle. Pioneering topics should be early research and development investment into promising therapeutic agents and standardization issues in testing procedures involving computational (in silico) modeling, bacteria, human stem cells and tissues, and animal models. Next to preclinical drug development, we shall welcome clinical studies on human patients, whose content reflects on trial metrics, and standards of efficiency, performance, progress, or quality measurements. Particularly, we invite submissions referring to transnational comparability and standardization issues related to major regional associations such as the ASEAN, Eur-Asian Union, European Union, and North American Treaty Organization. Original research and review pieces synthesizing evidence on good laboratory practice (GLP), good manufacturing practice (GMP), and good clinical practice (GCP) in respect of their role within the wider International Conference on Harmonization of pharmaceutical legislation will be given prominent place within our Section. Research exploring primary and outpatient pharmaceutical care and home-based care issues, across an array of world regions inclusive of OECD, low- and middle-income countries (LMICs), and emerging markets are warmly welcomed. Last but not least, pieces exploring hospital accreditation process and pharmaceutical production line establishment, in light of evolving pharmaceutical technology standards, remain within the focus of attention of our targeted audience. All sorts of articles designated as per MDPI publishing policies are welcomed.

  • Drug Standards
  • Drug life cycle 
  • Research and development
  • Preclinical drug development
  • Computational (in silico) modeling
  • Human stem cells
  • Animal model
  • Clinical trial
  • Standards of efficiency
  • Quality measurements
  • Good laboratory practice (GLP)
  • Good manufacturing practice (GMP)
  • Good clinical practice (GCP)
  • International Conference on Harmonization (ICH)
  • Pharmaceutical legislation
  • Pharmaceutical technology
  • Social pharmacy
  • Hospital accreditation
  • Pharmaceutical manufacturing
  • OECD
  • Low- and middle-income countries (LMICs)
  • Emerging markets
  • Asia-Pacific

Editorial Board

Special Issue

Following special issue within this section is currently open for submissions:

Papers Published

Back to TopTop